NMDA receptors on the surface of cancer cells: Target for chemotherapy?

Biomedicine and Pharmacotherapy

Volumn 68, Issue 4, 2014, Pages 493-496

  Deutsch, Stephen I ^a   Tang, Amy H ^a   Burket, Jessica A ^a   Benson, Andrew D ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Cancer; Chemotherapy; MTOR; NMDA receptor

Indexed keywords

DIZOCILPINE; GLUTAMATE RECEPTOR; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; LIGAND; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ASTROCYTOMA; BREAST CARCINOMA; CANCER CELL; CANCER CELL LINE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL DIFFERENTIATION; CELL DIVISION; CELL GROWTH; CELL INVASION; COLON ADENOCARCINOMA; DNA METHYLATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HUMAN; KERATINOCYTE; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; MEDULLOBLASTOMA; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; REVIEW; RHABDOMYOSARCOMA; SKIN CARCINOMA; STOMACH CANCER; THYROID CANCER; ANIMAL; CELL PROLIFERATION; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; LIGANDS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PHOSPHORYLATION; RECEPTORS, N-METHYL-D-ASPARTATE; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84901590248     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.03.012     Document Type: Review

References (21)

1. LoRusso P.M. Mammalian target of rapamycin as a rational therapeutic target for breast cancer treatment. Oncology 2013, 84:43-56.
2. Stepulak A., et al. NMDA antagonist inhibits the extracellular signal-regulated kinase pathway and suppresses cancer growth. Proc Natl Acad Sci U S A 2005, 102:15605-15610.
3. Stepulak A., et al. Expression of glutamate receptor subunits in human cancers. Histochem Cell Biol 2009, 132:435-445.
4. North W.G., Gao G., Jensen A., Memoli V.A., Du J. NMDA receptors are expressed by small-cell lung cancer and are potential targets for effective treatment. Clin Pharmacol 2010, 2:31-40.
5. North W.G., Gao G., Memoli V.A., Pang R.H., Lynch L. Breast cancer expresses functional NMDA receptors. Breast Cancer Res Treat 2010, 122:307-314.
6. Millan M.J. N-Methyl-d-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Psychopharmacology (Berl) 2005, 179:30-53.
7. Hess D.T., Stamler J.S. Regulation by S-nitrosylation of protein post-translational modification. J Biol Chem 2012, 287:4411-4418.
8. Ogden K.K., Traynelis S.F. New advances in NMDA receptor pharmacology. Trends Pharmacol Sci 2011, 32:726-733.
9. Korinek M., et al. Neurosteroid modulation of N-methyl-d-aspartate receptors: molecular mechanism and behavioral effects. Steroids 2011, 76:1409-1418.
10. Huang Y., et al. The cationic amino acid transporters CAT1 and CAT3 mediate nmda receptor activation-dependent changes in elaboration of neuronal processes via the mammalian target of rapamycin mTOR pathway. J Neurosci 2007, 27:449-458.
11. Fitzpatrick C.J., Lombroso P.J. The role of striatal-enriched protein tyrosine phosphatase (STEP) in cognition. Front Neuroanat 2011, 5:47.
12. Paul S., Nairn A.C., Wang P., Lombroso P.J. NMDA-mediated activation of the tyrosine phosphatase STEP regulates the duration of ERK signaling. Nat Neurosci 2003, 6:34-42.
13. Petroulakis E., Mamane Y., Le Bacquer O., Shahbazian D., Sonenberg N. mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer 2005, 94:195-199.
14. Markert J.M., et al. Differential gene expression profiling in human brain tumors. Physiol Genomics 2001, 5:21-33.
15. Nahm W.K., et al. Significance of N-methyl-d-aspartate (NMDA) receptor-mediated signaling in human keratinocytes. J Cell Physiol 2004, 200:309-317.
16. Tamura H., et al. Aberrant methylation of N-methyl-d-aspartate receptor type 2B (NMDAR2B) in non-small cell carcinoma. BMC Cancer 2011, 11:220.
17. Kim M.S., et al. N-methyl-d-aspartate receptor type 2B is epigenetically inactivated and exhibits tumor-suppressive activity in human esophageal cancer. Cancer Res 2006, 66:3409-3418.
18. Liu J.-W., et al. Quantitative hypermethylation of NMDAR2B in human gastric cancer. Int J Cancer 2007, 121:1994-2000.
19. Rzeski W., Turski L., Ikonomidou C. Glutamate antagonists limit tumor growth. Proc Natl Acad Sci U S A 2001, 98:6372-6377.
20. Choi S.-W., et al. The expression of NMDA receptor 1 is associated with clinicopathological parameters and prognosis in the oral squamous cell carcinoma. J Oral Pathol Med 2004, 33:533-537.
21. Abdul M., Hoosein N. N-methyl-d-aspartate receptor in human prostate cancer. J Membr Biol 2005, 205:125-128.